Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma

• Asıl Yazarlar: Sorana G. Pisano (Yazar), Sarah E. Hoffman (Yazar), Carlo S. Legasto (Yazar), Eric M. McLaughlin (Yazar), Kyle Porter (Yazar), James L. Chen (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2019-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Pazopanib (PAZ), a tyrosine kinase inhibitor used in the treatment of soft tissue sarcoma (STS), should not be administered with acid‐suppressive medications (ASMs) due to decreased drug solubility. Common practice for patients requiring ASM with PAZ is to separate administration by 12 hours; howeve...